*18 May 2011* * * *New Delhi :* Suven Life Sciences today said it has completed trials on animals of its 'SUVN-502' molecule, which is to be developed for treatment of central nervous system disorders like Alzheimer's disease and schizophrenia.
"SUVN-502 has completed all long-term chronic studies like 6-month rat tox, 9-month dog tox and development tox studies... very successfully and demonstrated a very high margin of safety," Suven said in a filing to the Bombay Stock Exchange (BSE). The regulatory toxicological studies are essential for Food and Drug Administration (FDA) approval to initiate the second phase of human trials in the patient population, the company added. Earlier, the company had tested the new molecule for human phase-I trials in Switzerland. "The potential market opportunity is more than USD 20 billion globally," Suven Life Sciences CEO Venkat Jasti said. http://ptinews.com/news/1601883_Suven-completes-animal-trials-of-CNS-molecule- -- You received this message because you are subscribed to the Google Groups "Mental Health Advocacy (News 'N Views) India" group. To post to this group, send email to [email protected] To unsubscribe from this group, send email to [email protected] For more options, visit this group at http://groups.google.com/group/MhaNewsViewsIndia?hl=en ------------- Affiliated Groups : MENTAL HEALTH ADVOCACY INDIA [email protected] Discussions on mental health law / policy / plan monitoring / human rights etc [email protected] India-specific news and views related to mental health [email protected] Information and support to carers of people with mental health issues [email protected] Mutual support and sharing of experiential knowledge, skills and social learning amongst peers
